Literature DB >> 17875717

Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?

Feyruz V Rassool1, Terry J Gaymes, Nader Omidvar, Nicola Brady, Stephanie Beurlet, Marika Pla, Murielle Reboul, Nicholas Lea, Christine Chomienne, Nicholas S B Thomas, Ghulam J Mufti, Rose Ann Padua.   

Abstract

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of disorders characterized by ineffective hematopoiesis, with an increased propensity to develop acute myelogenous leukemia (AML). The molecular basis for MDS progression is unknown, but a key element in MDS disease progression is loss of chromosomal material (genomic instability). Using our two-step mouse model for myeloid leukemic disease progression involving overexpression of human mutant NRAS and BCL2 genes, we show that there is a stepwise increase in the frequency of DNA damage leading to an increased frequency of error-prone repair of double-strand breaks (DSB) by nonhomologous end-joining. There is a concomitant increase in reactive oxygen species (ROS) in these transgenic mice with disease progression. Importantly, RAC1, an essential component of the ROS-producing NADPH oxidase, is downstream of RAS, and we show that ROS production in NRAS/BCL2 mice is in part dependent on RAC1 activity. DNA damage and error-prone repair can be decreased or reversed in vivo by N-acetyl cysteine antioxidant treatment. Our data link gene abnormalities to constitutive DNA damage and increased DSB repair errors in vivo and provide a mechanism for an increase in the error rate of DNA repair with MDS disease progression. These data suggest treatment strategies that target RAS/RAC pathways and ROS production in human MDS/AML.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875717     DOI: 10.1158/0008-5472.CAN-06-4807

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  58 in total

1.  Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.

Authors:  Emanuela Messa; Sonia Carturan; Chiara Maffè; Marisa Pautasso; Enrico Bracco; Antonella Roetto; Francesca Messa; Francesca Arruga; Ilaria Defilippi; Valentina Rosso; Chiara Zanone; Antonia Rotolo; Elisabetta Greco; Rosa M Pellegrino; Daniele Alberti; Giuseppe Saglio; Daniela Cilloni
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

Review 2.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

3.  Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome.

Authors:  Shohei Kikuchi; Masayoshi Kobune; Satoshi Iyama; Tsutomu Sato; Kazuyuki Murase; Yutaka Kawano; Kohichi Takada; Kaoru Ono; Tsuyoshi Hayashi; Koji Miyanishi; Yasushi Sato; Rishu Takimoto; Junji Kato
Journal:  Int J Hematol       Date:  2012-03-11       Impact factor: 2.490

Review 4.  Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Authors:  H Sill; W Olipitz; A Zebisch; E Schulz; A Wölfler
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

5.  Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.

Authors:  Enrique Colado; Teresa Paíno; Patricia Maiso; Enrique M Ocio; Xi Chen; Stela Alvarez-Fernández; Norma C Gutiérrez; Jesús Martín-Sánchez; Juan Flores-Montero; Laura San Segundo; Mercedes Garayoa; Diego Fernández-Lázaro; Maria-Belen Vidriales; Carlos M Galmarini; Pablo Avilés; Carmen Cuevas; Atanasio Pandiella; Jesús F San-Miguel
Journal:  Haematologica       Date:  2011-02-17       Impact factor: 9.941

6.  Human induced pluripotent cells resemble embryonic stem cells demonstrating enhanced levels of DNA repair and efficacy of nonhomologous end-joining.

Authors:  Jinshui Fan; Carine Robert; Yoon-Young Jang; Hua Liu; Saul Sharkis; Stephen Bruce Baylin; Feyruz Virgilia Rassool
Journal:  Mutat Res       Date:  2011-06-28       Impact factor: 2.433

Review 7.  Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.

Authors:  Mary E Irwin; Nilsa Rivera-Del Valle; Joya Chandra
Journal:  Antioxid Redox Signal       Date:  2012-09-28       Impact factor: 8.401

Review 8.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Authors:  Stephanie Beurlet; Christine Chomienne; Rose Ann Padua
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

9.  Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy.

Authors:  Masayuki Nitta; David Kozono; Richard Kennedy; Jayne Stommel; Kimberly Ng; Pascal O Zinn; Deepa Kushwaha; Santosh Kesari; Maria-del-Mar Inda; Jill Wykosky; Frank Furnari; Katherine A Hoadley; Lynda Chin; Ronald A DePinho; Webster K Cavenee; Alan D'Andrea; Clark C Chen
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

10.  Iron chelation therapy in myelodysplastic syndromes.

Authors:  Emanuela Messa; Daniela Cilloni; Giuseppe Saglio
Journal:  Adv Hematol       Date:  2010-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.